U.S. FDA Approves First ANDA Generic Flovent® HFA in 110 mcg and 220 mcg strengths for the Treatment of Asthma

- **Product jointly developed by Cipla and Teva Pharmaceuticals**
- **Cipla responsible for manufacturing and supply**
- **Teva holds ANDA and will commercialize the product**

Mumbai, India, November 25, 2026 – Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as "Cipla") today announced the U.S. FDA approval and launch of Fluticasone HFA MDI, the first generic equivalent Flovent® HFA, in110 mcg and 220 mcg strengths, approved under an Abbreviated New Drug Application (ANDA).

Cipla and Teva Pharmaceuticals (hereinafter referred to as "Teva"), jointly developed the product. Cipla is responsible for manufacturing and supplying the product, while Teva holds the ANDA to the product and will commercialize the product in the United States.

Fluticasone HFA is an inhaled corticosteroid indicated for the long-term maintenance and prophylactic treatment of asthma in patients aged 4 years and older, as well as for patients requiring oral corticosteroid therapy for asthma.

Commenting on the milestone, **Achin Gupta, Managing Director & Global Chief Executive Officer, Cipla**, said, "Respiratory care has long been a core strength for Cipla, and our purpose remains rooted in improving the lives of patients. This product reinforces our commitment to expanding access to trusted treatment options for patients living with asthma".

Marc Falkin, Chief Executive Officer, Cipla North America, said, "We are delighted to see this opportunity create meaningful impact and support our future US growth journey. Our team remains focused on consistent supply to service the market."

According to IQVIA, the U.S. market for fluticasone HFA 110 and 220 mcg is approximately $350 million.

About Cipla Limited

Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments are well-known. Our 48 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to

our 80+ markets. Cipla is ranked 3rd largest in pharma in India (IQVIA MAT Sep'26), 2nd largest in the pharma prescription market in South Africa (IQVIA MAT Aug'26), and 2nd largest by prescription in the US Gx (Repulses + MDI) products (IQVIA MAT Sep'26). For over eight decades, making a difference to patients has inspired every aspect of Cipla's work. Our paradigm-changing offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. A responsible corporate citizen, Cipla's humanitarian approach to healthcare in pursuit of its purpose of 'Caring for Life' and deep-rooted community links wherever it is present make it a partner of choice to global health bodies, peers and all stakeholders. For more, please visit www.cipla.com, or click on Twitter, Facebook, LinkedIn.

Media Contacts:

Corporate Communications
Heena Kanal
E-Mail: CorpComm@cipla.com

Investor Relations
Diksha Maheshwari
E-Mail: Investor.Relations@cipla.com